Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications
Open Access
- 3 February 2025
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 223
Abstract
The mitochondrial pyruvate carrier (MPC) is a transmembrane protein complex critical for cellular energy metabolism, enabling the transport of pyruvate from the cytosol into the mitochondria, where it fuels the citric acid cycle. By regulating this essential entry point of carbon into mitochondrial metabolism, MPC is pivotal for maintaining cellular energy balance and metabolic flexibility. Dysregulation of MPC activity has been implicated in several metabolic disorders, including type 2 diabetes, obesity, and cancer, underscoring its potential as a therapeutic target. This review provides an overview of the MPC complex, examining its structural components, regulatory mechanisms, and biological functions. We explore the current understanding of transcriptional, translational, and post-translational modifications that modulate MPC function and highlight the clinical relevance of MPC dysfunction in metabolic and neurodegenerative diseases. Progress in the development of MPC-targeting therapeutics is discussed, with a focus on challenges in designing selective and potent inhibitors. Emphasis is placed on modern approaches for identifying novel inhibitors, particularly virtual screening and computational strategies. This review establishes a foundation for further research into the medicinal chemistry of MPC inhibitors, promoting advances in structure-based drug design to develop therapeutics for metabolic and neurodegenerative diseases.Keywords
This publication has 99 references indexed in Scilit:
- The Role of Mitochondrial Pyruvate Carrier in Neurological DisordersMolecular Neurobiology, 2024
- Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s DiseaseMolecular Neurobiology, 2022
- Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ ActivityHepatology Communications, 2021
- QSAR models for prediction study of HIV protease inhibitors using support vector machines, neural networks and multiple linear regressionArabian Journal of Chemistry, 2017
- Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitisHepatology, 2016
- The mitochondrial pyruvate carrier in health and disease: To carry or not to carry?Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Regulation of pyruvate metabolism and human diseaseCellular and Molecular Life Sciences, 2013
- On Exploring Structure–Activity Relationships2013
- Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrierBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2005
- The transport of pyruvate in rat liver mitochondriaFEBS Letters, 1971